[go: up one dir, main page]

NO20050956L - Method and dosage forms for controlled delivery of paliperidone - Google Patents

Method and dosage forms for controlled delivery of paliperidone

Info

Publication number
NO20050956L
NO20050956L NO20050956A NO20050956A NO20050956L NO 20050956 L NO20050956 L NO 20050956L NO 20050956 A NO20050956 A NO 20050956A NO 20050956 A NO20050956 A NO 20050956A NO 20050956 L NO20050956 L NO 20050956L
Authority
NO
Norway
Prior art keywords
paliperidone
dosage forms
controlled delivery
delivery
controlled
Prior art date
Application number
NO20050956A
Other languages
Norwegian (no)
Other versions
NO324821B1 (en
Inventor
Atul Devdatt Ayer
Noymi Yam
Iran Reyes
Nipun Davar
Julie Lee
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050956(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20050956L publication Critical patent/NO20050956L/en
Publication of NO324821B1 publication Critical patent/NO324821B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20050956A 2002-07-29 2005-02-22 Dosage form comprising paliperidone or risperidone at substantially increasing release rate and use of paliperidone or risperidone NO324821B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26
PCT/US2003/023433 WO2004010981A1 (en) 2002-07-29 2003-07-28 Methods and dosage forms for controlled delivery of paliperidone

Publications (2)

Publication Number Publication Date
NO20050956L true NO20050956L (en) 2005-04-27
NO324821B1 NO324821B1 (en) 2007-12-10

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050956A NO324821B1 (en) 2002-07-29 2005-02-22 Dosage form comprising paliperidone or risperidone at substantially increasing release rate and use of paliperidone or risperidone

Country Status (28)

Country Link
US (1) US20040092534A1 (en)
EP (1) EP1539115B1 (en)
JP (1) JP4500679B2 (en)
KR (1) KR100699516B1 (en)
CN (1) CN1684670A (en)
AR (1) AR040721A1 (en)
AT (1) ATE373472T1 (en)
AU (1) AU2003256844A1 (en)
BR (1) BR0313139A (en)
CA (1) CA2494234C (en)
CO (1) CO5580742A2 (en)
CY (1) CY1107096T1 (en)
DE (1) DE60316454T2 (en)
DK (1) DK1539115T3 (en)
ES (1) ES2293039T3 (en)
HR (1) HRP20050077B1 (en)
IL (1) IL166489A (en)
MX (1) MXPA05001191A (en)
MY (1) MY137049A (en)
NO (1) NO324821B1 (en)
NZ (1) NZ570198A (en)
PE (1) PE20040132A1 (en)
PL (1) PL210119B1 (en)
PT (1) PT1539115E (en)
RU (1) RU2321391C2 (en)
TW (1) TWI363637B (en)
WO (1) WO2004010981A1 (en)
ZA (1) ZA200501641B (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2005271522B2 (en) * 2004-08-04 2011-02-10 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
JP2009507774A (en) * 2005-08-04 2009-02-26 アルザ・コーポレーシヨン Osmotic dosage form comprising a semi-permeable membrane with a polymer mixture providing improved properties
WO2007081736A1 (en) * 2006-01-06 2007-07-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
SI3095447T1 (en) 2006-02-03 2022-02-28 Opko Renal, Llc Treatment shortages vitamin D s 25-hydroxyvitamin D2 in 25-hydroxyvitamin D3
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
PL3542792T3 (en) 2007-04-25 2023-11-20 Eirgen Pharma Ltd. Controlled release 25-hydroxyvitamin d
EP3225243B1 (en) * 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
PL2079446T3 (en) * 2007-08-21 2012-04-30 Teva Pharma Paliperidone sustained release formulation
BRPI0817946A2 (en) 2007-09-25 2015-05-05 Teva Pharma Stable imatinib compositions
EP3909585A1 (en) * 2007-12-19 2021-11-17 Janssen Pharmaceutica NV Dosing regimen associated with long acting injectable paliperidone esters
EP2280967A2 (en) * 2008-03-27 2011-02-09 Actavis Group PTC EHF Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
EP2326312A1 (en) * 2008-07-25 2011-06-01 KRKA, D.D., Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
WO2010044097A2 (en) 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
CA2739181C (en) * 2008-09-30 2017-03-14 Endo Pharmaceuticals Solutions Inc. Implantable device for the delivery of risperidone and methods of use thereof
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
CA2777856A1 (en) * 2009-10-16 2011-04-21 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
US9271939B2 (en) 2010-03-15 2016-03-01 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
RS60087B1 (en) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Methods and compositions for reducing parathyroid levels
ES2602503T3 (en) 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. Organic compounds
US20120201886A1 (en) 2010-07-30 2012-08-09 Micro Labs Limited Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
CN102058517A (en) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 Paliperidone slow release formulation and preparation method thereof
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (en) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 Sustained release gel for injection for paliperidone and paliperidone derivative
US20150080404A1 (en) 2012-04-14 2015-03-19 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
PT2968320T (en) 2013-03-15 2021-01-28 Intra Cellular Therapies Inc Organic compounds
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
CN103271889B (en) * 2013-05-23 2015-10-28 沈阳药科大学 Novel paliperidone progressively-increarelease release osmotic pump preparation and preparation method thereof
CN103385857A (en) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 Pharmaceutical composition of palipeddone
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
KR102692169B1 (en) 2013-12-03 2024-08-05 인트라-셀룰라 써래피스, 인코퍼레이티드. Novel methods
ES2961843T3 (en) 2014-04-04 2024-03-14 Intra Cellular Therapies Inc Deuterated heterocycle-condensed gamma-carbolines as antagonists of 5-HT2A receptors
CN106456638A (en) 2014-04-04 2017-02-22 细胞内治疗公司 Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (en) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 Paliperidone controlled-release tablet and preparation method thereof
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (en) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Pharmaceutical formulation containing an atypical antipsychotic factor- preparation method thereof
CN105147629B (en) * 2015-09-24 2017-08-25 吉林大学 A kind of sharp ketone tablet of isobutyl and preparation method
HUE053737T2 (en) 2016-01-26 2021-07-28 Intra Cellular Therapies Inc Pyridopyrroloquinoxaline compounds, their preparations and their uses
KR102483124B1 (en) 2016-03-25 2022-12-29 인트라-셀룰라 써래피스, 인코퍼레이티드. organic compounds
AU2017253821B2 (en) 2016-03-28 2022-11-03 Opko Ireland Global Holdings, Limited Methods of vitamin D treatment
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017174096A1 (en) 2016-04-05 2017-10-12 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018098115A1 (en) * 2016-11-23 2018-05-31 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
CN106727392A (en) * 2016-12-15 2017-05-31 上海奕利制药有限公司 A kind of 9-hydroxy-risperidone sustained-release tablet and preparation method thereof
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JP7132939B2 (en) 2017-03-24 2022-09-07 イントラ－セルラー・セラピーズ・インコーポレイテッド Novel compositions and methods
AU2018307479B2 (en) 2017-07-26 2024-06-20 Intra-Cellular Therapies, Inc. Organic compounds
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
BR112020019181A2 (en) 2018-03-23 2021-01-05 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
CN112040940A (en) 2018-03-23 2020-12-04 细胞内治疗公司 Organic compounds
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
US10695345B2 (en) 2018-08-31 2020-06-30 Intra-Cellular Therapies, Inc. Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
KR102906995B1 (en) 2018-08-31 2025-12-31 인트라-셀룰라 써래피스, 인코퍼레이티드. A new method
EP3993798A4 (en) 2019-07-07 2023-04-26 Intra-Cellular Therapies, Inc. NEW PROCESSES
KR102285510B1 (en) 2019-10-29 2021-08-04 강동국 Capsule for controlling concentration of nutrient solution and use of the same
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE SUSTAINED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
CN113616610B (en) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 Paliperidone sustained release tablet and preparation method thereof
US20230364009A1 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of an Antipsychotic
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN120417904A (en) 2022-12-30 2025-08-01 细胞内治疗公司 Heterocyclic fused γ-carbolines acting on serotonin 5-HT2A receptors
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EP1029538A3 (en) * 1993-09-28 2003-10-15 R.P. Scherer GmbH Soft gelatin capsule manufacture
SK282231B6 (en) * 1993-11-19 2001-12-03 Janssen Pharmaceutica N. V. PHARMACEUTICAL MEDICINAL PRODUCT FOR THE TREATMENT OF PSYCHOTIC DISORDERS
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CA2263558A1 (en) * 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
WO1999062496A1 (en) * 1998-06-03 1999-12-09 Alza Corporation Methods and devices for providing prolonged drug therapy
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
DK1126853T3 (en) * 1998-11-02 2006-08-14 Alza Corp Controlled delivery of antidepressants
CA2354472C (en) * 1998-12-17 2009-02-24 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
ES2255490T3 (en) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. PREGELATINIZED ALMIDON IN A CONTROLLED RELEASE FORMULATION.
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
WO2004010981A1 (en) 2004-02-05
CN1684670A (en) 2005-10-19
DE60316454T2 (en) 2008-06-26
TW200418524A (en) 2004-10-01
NZ570198A (en) 2010-01-29
PT1539115E (en) 2008-01-14
BR0313139A (en) 2005-07-05
CA2494234C (en) 2009-10-27
IL166489A (en) 2014-01-30
IL166489A0 (en) 2006-01-15
PE20040132A1 (en) 2004-03-06
KR100699516B1 (en) 2007-03-26
CY1107096T1 (en) 2012-10-24
JP2005535682A (en) 2005-11-24
NO324821B1 (en) 2007-12-10
ES2293039T3 (en) 2008-03-16
RU2321391C2 (en) 2008-04-10
HRP20050077A2 (en) 2005-12-31
AU2003256844A1 (en) 2004-02-16
KR20050044895A (en) 2005-05-13
DE60316454D1 (en) 2007-10-31
RU2005102105A (en) 2005-08-10
ATE373472T1 (en) 2007-10-15
PL210119B1 (en) 2011-12-30
JP4500679B2 (en) 2010-07-14
DK1539115T3 (en) 2008-01-28
EP1539115A1 (en) 2005-06-15
CO5580742A2 (en) 2005-11-30
TWI363637B (en) 2012-05-11
MXPA05001191A (en) 2005-09-12
EP1539115B1 (en) 2007-09-19
HRP20050077B1 (en) 2013-11-22
US20040092534A1 (en) 2004-05-13
PL376258A1 (en) 2005-12-27
AR040721A1 (en) 2005-04-20
CA2494234A1 (en) 2004-02-05
ZA200501641B (en) 2005-08-31
HK1072559A1 (en) 2005-09-02
MY137049A (en) 2008-12-31

Similar Documents

Publication Publication Date Title
NO20050956L (en) Method and dosage forms for controlled delivery of paliperidone
NO20042993L (en) Formulation and dosage form for controlled delivery of therapeutic agents
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
NO20031581D0 (en) Method and system for authenticating components of a graphics system
FI20012017A0 (en) Method and apparatus for dose calculation of magnetic stimulation
DK1415535T4 (en) Spraying system and method for such
EP1478345A4 (en) Novel pharmaceutical dosage forms and method for producing same
AU2003265618A8 (en) Method and apparatus of position location
DK1673214T3 (en) APPARATUS AND METHOD OF SLAM TREATMENT
SG116507A1 (en) Pharmaceutical dosage form and method of making.
NO20053874D0 (en) Formulation and methods of treatment of thrombocytemia
NO20030438L (en) Method and apparatus for casting concrete products
NO20044342L (en) Androgenic pharmaceutical preparation and method of treating depression
NO20041076L (en) Plant and method of stopping, especially of electrodes
SG103888A1 (en) Method and apparatus for the control of building functional units
IS2326B (en) System and method of generating charge units
GB0203518D0 (en) Wager administration system and method of operation thereof
NO20033155D0 (en) Method of hormone replacement therapy and its method of administration
IL162716A0 (en) Oral pharmaceutical compositions for soft capsulescontaining vinorelbine and method of treatment
GB0208897D0 (en) New method of treatment
GB0205894D0 (en) Method and apparatus for the administration of benefits
SI1539115T1 (en) Methods and dosage forms for controlled delivery of paliperidone
NO20043238L (en) Nelfinavir tablet with increased dosage and method of preparation thereof
GB0213198D0 (en) Method of treatment
GB0201324D0 (en) Method of and apparatus for account

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees